<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03667053</url>
  </required_header>
  <id_info>
    <org_study_id>ZP4207-17086</org_study_id>
    <nct_id>NCT03667053</nct_id>
  </id_info>
  <brief_title>Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in T1DM Children</brief_title>
  <official_title>Phase 3, Randomized, Double-blind, Placebo/Active-controlled, Parallel-arm Trial to Assess Efficacy, Safety, and Pharmacokinetics of Dasiglucagon Relative to Placebo/GlucaGen® as Rescue Therapy for Severe Hypoglycemia in Children With T1DM Treated With Insulin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zealand Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zealand Pharma</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 3, randomized, double-blind, placebo- and active-controlled, parallel-arm trial to&#xD;
      assess the efficacy, safety, and pharmacokinetics of dasiglucagon relative to placebo and&#xD;
      GlucaGen® when administered as a rescue therapy for severe hypoglycemia in children with type&#xD;
      1 diabetes mellitus (T1DM) treated with insulin&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At least 40 children ≥6 years and &lt;18 years of age with T1DM were planned to be randomized&#xD;
      into the trial (2:1:1 for dasiglucagon:placebo:GlucaGen) and stratified by age intervals: 6&#xD;
      years to &lt;12 years, and 12 years to &lt;18 years; and by injection site (abdomen or thigh). A&#xD;
      minimum of 16 patients were enrolled into each age group, including a minimum of 8 patients&#xD;
      in each age group in the dasiglucagon treatment arm. In Germany only, a staggered approach&#xD;
      was applied, whereby a positive safety assessment needed to be available for at least 10&#xD;
      patients in the age group of 12 years to &lt;18 years who had completed the dosing visit in the&#xD;
      overall trial before younger patients (6 to 11 years of age) were allowed to be enrolled.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 28, 2018</start_date>
  <completion_date type="Actual">June 28, 2019</completion_date>
  <primary_completion_date type="Actual">June 28, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Plasma Glucose Recovery</measure>
    <time_frame>0-45 minutes after dosing</time_frame>
    <description>Plasma glucose recovery was defined as first increase in plasma glucose of ≥20 mg/dL (1.1 mmol/L) from baseline during the hypoglycemic clamp procedure without administration of rescue intravenous (IV) glucose. Patients who received rescue IV glucose before 45 minutes and patients not recovering within 45 minutes after dosing were censored at 45 minutes. Time to plasma glucose recovery was summarized for each treatment group using Kaplan Meier (KM) estimates together with the 95% confidence interval.&#xD;
Note that the upper confidence limit for the placebo median was not estimable, but is set to 45 minutes (censored value) here.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Glucose Recovery</measure>
    <time_frame>0-30 minutes after dosing: assessed at 10, 15, 20 and 30 minutes after study drug injection</time_frame>
    <description>Plasma glucose recovery within 30 minutes, within 20 minutes, within 15 minutes, and within 10 minutes after study drug injection without administration of rescue intravenous (IV) glucose. Plasma glucose recovery was defined as the first increase in plasma glucose of ≥20 mg/dL (1.1 mmol/L) from baseline without administration of rescue intravenous glucose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Glucose Changes From Baseline</measure>
    <time_frame>0-30 minutes after dosing: assessed at 10, 15, 20 and 30 minutes after study drug injection</time_frame>
    <description>Plasma glucose changes from baseline within 30 minutes, within 20 minutes, within 15 minutes, and within 10 minutes after trial product injection or at the time of rescue intravenous (IV) glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics - Area Under the Effect Curve (0-30 Minutes)</measure>
    <time_frame>0-30 minutes</time_frame>
    <description>Plasma glucose response as area under the effect curve above baseline from time 0 to 30 minutes (AUE0-30min). Plasma glucose was determined at pre-dose and at 4, 6, 8, 10, 12, 15, 17, 20, 30, and 45 minutes (and at 60 minutes if the patient weighed ≥21 kg) after dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Administration of Rescue IV Glucose Infusion After IMP Injection</measure>
    <time_frame>0-45 minutes</time_frame>
    <description>Number of patients receiving IV rescue glucose administration for hypoglycemia after administration of IMP. IV = intravenous. IMP = investigational medicinal product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First IV Glucose Infusion After IMP Administration</measure>
    <time_frame>0-45 minutes</time_frame>
    <description>Time to first IV rescue glucose administration for hypoglycemia after administration of IMP. IV = intravenous. IMP = investigational medicinal product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: AUC0-30 Min</measure>
    <time_frame>0-30 minutes</time_frame>
    <description>Area under the plasma dasiglucagon or GlucaGen concentration versus time curve from 0 to 30 minutes post-dose. Samples were collected before dosing and at 10, 20, 30, 40, 60, 90, 140, 220, and 300 minutes after dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: AUC0-300min</measure>
    <time_frame>0-300 minutes</time_frame>
    <description>Area under the plasma dasiglucagon or GlucaGen concentration versus time curve from 0 to 300 minutes post-dose. Samples were collected before dosing and at 10, 20, 30, 40, 60, 90, 140, 220, and 300 minutes after dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: AUC0-inf</measure>
    <time_frame>0-300 minutes</time_frame>
    <description>Area under the plasma dasiglucagon or GlucaGen concentration versus time curve from 0 to infinitely post-dose. Samples were collected before dosing and at 10, 20, 30, 40, 60, 90, 140, 220, and 300 minutes after dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Cmax</measure>
    <time_frame>0-300 minutes</time_frame>
    <description>Maximum of all valid plasma dasiglucagon or GlucaGen concentration measurements from 0 to 300 minutes post-dose. Samples were collected before dosing and at 10, 20, 30, 40, 60, 90, 140, 220, and 300 minutes after dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Tmax</measure>
    <time_frame>0-300 minutes</time_frame>
    <description>Time to maximum of plasma dasiglucagon or GlucaGen concentration measurements. Samples were collected before dosing and at 10, 20, 30, 40, 60, 90, 140, 220, and 300 minutes after dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: λz</measure>
    <time_frame>0-300 minutes</time_frame>
    <description>Terminal elimination rate constant of plasma dasiglucagon or GlucaGen. Samples were collected before dosing and at 10, 20, 30, 40, 60, 90, 140, 220, and 300 minutes after dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: t½</measure>
    <time_frame>0-300 minutes</time_frame>
    <description>Terminal plasma elimination half-life of dasiglucagon or GlucaGen. Samples were collected before dosing and at 10, 20, 30, 40, 60, 90, 140, 220, and 300 minutes after dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: CL/f</measure>
    <time_frame>0-300 minutes</time_frame>
    <description>Total body clearance of plasma dasiglucagon or GlucaGen. Samples were collected before dosing and at 10, 20, 30, 40, 60, 90, 140, 220, and 300 minutes after dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Vz/f</measure>
    <time_frame>0-300 minutes</time_frame>
    <description>Volume of distribution of plasma dasiglucagon or GlucaGen. Samples were collected before dosing and at 10, 20, 30, 40, 60, 90, 140, 220, and 300 minutes after dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: MRT</measure>
    <time_frame>0-300 minutes</time_frame>
    <description>Mean residence time of plasma dasiglucagon or GlucaGen. Samples were collected before dosing and at 10, 20, 30, 40, 60, 90, 140, 220, and 300 minutes after dosing.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Hypoglycemia</condition>
  <arm_group>
    <arm_group_label>dasiglucagon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single fixed dose (s.c.injection) of dasiglucagon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single fixed dose (s.c.injection) of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GlucaGen®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single fixed dose (s.c.injection) of GlucaGen®</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dasiglucagon</intervention_name>
    <description>glucagon analog</description>
    <arm_group_label>dasiglucagon</arm_group_label>
    <other_name>ZP4207</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo for dasiglucagon</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>placebo for dasiglucagon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GlucaGen HypoKit</intervention_name>
    <description>native glucagon</description>
    <arm_group_label>GlucaGen®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Following receipt of verbal and written information about the trial, patient,&#xD;
             parent(s) or guardian(s) of the patient must provide signed informed consent before&#xD;
             any trial-related activity is carried out&#xD;
&#xD;
          2. Female or male patients with T1DM for at least 1 year, diagnostic criteria as defined&#xD;
             by the American Diabetes Association; and receiving daily insulin&#xD;
&#xD;
          3. At least 6.0 years of age (inclusive) and less than 18.0 years&#xD;
&#xD;
          4. Body weight ≥20 kg&#xD;
&#xD;
          5. Female patients must meet one of the following criteria:&#xD;
&#xD;
             a. Participant is of childbearing potential and agrees to use one of the accepted&#xD;
             contraceptive regimens throughout the entire duration of the trial from screening&#xD;
             until last follow-up visit. An acceptable method of contraception includes at least&#xD;
             one of the following: i. Abstinence from heterosexual intercourse ii. Systemic&#xD;
             contraceptives (birth control pills, injectable/implant/ insertable hormonal birth&#xD;
             control products, transdermal patch); if the participant is using systemic&#xD;
             contraceptives, she must use an additional form of acceptable contraception (iii or&#xD;
             iv, below) iii. Intrauterine device (with and without hormones) iv. Condom with&#xD;
             spermicide or b. Participant is of non-childbearing potential due to pre-puberty&#xD;
             status or a medical condition confirmed by the investigator&#xD;
&#xD;
          6. Male patients must meet the following criteria: If sexually active, uses condom and&#xD;
             partner practices contraception during the trial from screening and until last&#xD;
             follow-up visit&#xD;
&#xD;
          7. Willingness to adhere to the protocol requirements&#xD;
&#xD;
             -&#xD;
&#xD;
             Exclusion Criteria:&#xD;
&#xD;
        1. Females who are pregnant according to a positive urine pregnancy test, actively&#xD;
        attempting to get pregnant, or are lactating 2. Known or suspected allergy to trial&#xD;
        product(s) or related products 3. History of anaphylaxis or symptoms of severe systemic&#xD;
        allergy (such as angioedema) 4. Previous randomization in this trial 5. History of an&#xD;
        episode of severe hypoglycemia that required a third party assistance within a month prior&#xD;
        to screening visit 6. History of hypoglycemic events associated with seizures or&#xD;
        hypoglycemia unawareness in the last year prior to screening 7. History of epilepsy or&#xD;
        seizure disorder 8. Receipt of any investigational drug within 3 months prior to screening&#xD;
        9. Active malignancy within the last 5 years 10. Congestive heart failure, New York Heart&#xD;
        Association class II-IV 11. Current bleeding disorder, including anti-coagulant treatment&#xD;
        12. Known presence or history of pheochromocytoma (i.e. adrenal gland tumor) or insulinoma&#xD;
        (i.e. insulin secreting pancreas tumor) 13. Use of a daily systemic beta-blocker drug,&#xD;
        indomethacin, warfarin or anticholinergic drugs in the previous 28 days before Day 1 of&#xD;
        this trial 14. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &gt;2.5 ×&#xD;
        the upper limit of the normal range (ULN), bilirubin &gt;1.5 × ULN, estimated glomerular&#xD;
        filtration rate &lt;30 mL/min/1.73 m2 according to the Modification of Diet in Renal Disease&#xD;
        study definition, or altered electrolyte values of clinical relevance for cardiac&#xD;
        conduction, as judged by the investigator 15. Clinically significant abnormal&#xD;
        electrocardiogram (ECG) at screening as judged by the investigator 16. Clinically&#xD;
        significant illness within 4 weeks before screening, as judged by the investigator 17.&#xD;
        Surgery or trauma with significant blood loss within the last 2 months prior to screening&#xD;
        18. Patients with mental incapacity or language barriers which preclude adequate&#xD;
        understanding or cooperation, who are unwilling to participate in the trial, or who in the&#xD;
        opinion of the investigator should not participate in the trial 19. Any condition&#xD;
        interfering with trial participation or evaluation or that could be hazardous to the&#xD;
        patient 20. The use of prescription or non-prescription medications known to cause QT&#xD;
        prolongation&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christina M Sylvest, MSc Pharm</last_name>
    <role>Study Director</role>
    <affiliation>Zealand Pharma A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AMCR Institute, Inc</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University, Department of Pediatrics</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auf der Bult - Diabetes Center for Children</name>
      <address>
        <city>Hannover</city>
        <zip>30173</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Ljubljana, Children's Hospital, Department for Endocrinology, Diabetes and Metabolism</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Slovenia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>September 7, 2018</study_first_submitted>
  <study_first_submitted_qc>September 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2018</study_first_posted>
  <results_first_submitted>April 13, 2021</results_first_submitted>
  <results_first_submitted_qc>April 13, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 10, 2021</results_first_posted>
  <disposition_first_submitted>June 4, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>June 4, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">June 5, 2020</disposition_first_posted>
  <last_update_submitted>May 31, 2021</last_update_submitted>
  <last_update_submitted_qc>May 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glucagon</keyword>
  <keyword>Dasiglucagon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 8, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/53/NCT03667053/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 16, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/53/NCT03667053/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dasiglucagon 0.6 mg</title>
          <description>Single fixed dose (subcutaneous injection) of dasiglucagon&#xD;
dasiglucagon: glucagon analog</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Single fixed dose (subcutaneous injection) of placebo&#xD;
placebo: placebo for dasiglucagon</description>
        </group>
        <group group_id="P3">
          <title>GlucaGen® 1.0 mg</title>
          <description>Single fixed dose (subcutaneous injection) of GlucaGen® (0.5 mg if body weight &lt;25 kg)&#xD;
GlucaGen HypoKit: native glucagon</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Randomized and Treated</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety analysis set of all randomized and treated participants. Treatment assignment was based on the treatment actually received.</population>
      <group_list>
        <group group_id="B1">
          <title>Dasiglucagon 0.6 mg</title>
          <description>Single fixed dose (subcutaneous injection) of dasiglucagon&#xD;
dasiglucagon: glucagon analog</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Single fixed dose (subcutaneous injection) of placebo&#xD;
placebo: placebo for dasiglucagon</description>
        </group>
        <group group_id="B3">
          <title>GlucaGen® 1.0 mg</title>
          <description>Single fixed dose (subcutaneous injection) of GlucaGen® (0.5 mg if body weight &lt;25 kg)&#xD;
GlucaGen HypoKit: native glucagon</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="41"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.3" spread="3.42"/>
                    <measurement group_id="B2" value="12.8" spread="3.25"/>
                    <measurement group_id="B3" value="12.4" spread="3.50"/>
                    <measurement group_id="B4" value="12.5" spread="3.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Age 6-11 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age 12-17 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slovenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.54" spread="22.202"/>
                    <measurement group_id="B2" value="54.95" spread="21.404"/>
                    <measurement group_id="B3" value="48.81" spread="14.992"/>
                    <measurement group_id="B4" value="51.79" spread="20.106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index</title>
          <units>kg per square meter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.74" spread="6.057"/>
                    <measurement group_id="B2" value="20.39" spread="4.885"/>
                    <measurement group_id="B3" value="18.92" spread="2.617"/>
                    <measurement group_id="B4" value="20.20" spread="5.050"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Plasma Glucose Recovery</title>
        <description>Plasma glucose recovery was defined as first increase in plasma glucose of ≥20 mg/dL (1.1 mmol/L) from baseline during the hypoglycemic clamp procedure without administration of rescue intravenous (IV) glucose. Patients who received rescue IV glucose before 45 minutes and patients not recovering within 45 minutes after dosing were censored at 45 minutes. Time to plasma glucose recovery was summarized for each treatment group using Kaplan Meier (KM) estimates together with the 95% confidence interval.&#xD;
Note that the upper confidence limit for the placebo median was not estimable, but is set to 45 minutes (censored value) here.</description>
        <time_frame>0-45 minutes after dosing</time_frame>
        <population>Full analysis set (same as the safety analysis set) of all randomized and treated patients. Treatment assignment was based on the randomized treatment. Assignment to the stratification factor injection site was based on the planned and not the actual used injection site.</population>
        <group_list>
          <group group_id="O1">
            <title>Dasiglucagon 0.6 mg</title>
            <description>Single fixed dose (subcutaneous injection) of dasiglucagon&#xD;
dasiglucagon: glucagon analog</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Single fixed dose (subcutaneous injection) of placebo&#xD;
placebo: placebo for dasiglucagon</description>
          </group>
          <group group_id="O3">
            <title>GlucaGen® 1.0 mg</title>
            <description>Single fixed dose (subcutaneous injection) of GlucaGen® (0.5 mg if body weight &lt;25 kg)&#xD;
GlucaGen HypoKit: native glucagon</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Plasma Glucose Recovery</title>
          <description>Plasma glucose recovery was defined as first increase in plasma glucose of ≥20 mg/dL (1.1 mmol/L) from baseline during the hypoglycemic clamp procedure without administration of rescue intravenous (IV) glucose. Patients who received rescue IV glucose before 45 minutes and patients not recovering within 45 minutes after dosing were censored at 45 minutes. Time to plasma glucose recovery was summarized for each treatment group using Kaplan Meier (KM) estimates together with the 95% confidence interval.&#xD;
Note that the upper confidence limit for the placebo median was not estimable, but is set to 45 minutes (censored value) here.</description>
          <population>Full analysis set (same as the safety analysis set) of all randomized and treated patients. Treatment assignment was based on the randomized treatment. Assignment to the stratification factor injection site was based on the planned and not the actual used injection site.</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.00" lower_limit="8.00" upper_limit="12.00"/>
                    <measurement group_id="O2" value="30.00" lower_limit="20.00" upper_limit="45.00"/>
                    <measurement group_id="O3" value="10.00" lower_limit="8.00" upper_limit="12.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The treatment group difference between dasiglucagon and placebo was evaluated inferentially using a pairwise two-sided log rank test stratified by injection site and age group.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Glucose Recovery</title>
        <description>Plasma glucose recovery within 30 minutes, within 20 minutes, within 15 minutes, and within 10 minutes after study drug injection without administration of rescue intravenous (IV) glucose. Plasma glucose recovery was defined as the first increase in plasma glucose of ≥20 mg/dL (1.1 mmol/L) from baseline without administration of rescue intravenous glucose.</description>
        <time_frame>0-30 minutes after dosing: assessed at 10, 15, 20 and 30 minutes after study drug injection</time_frame>
        <population>Full analysis set (same as the safety analysis set) of all randomized and treated patients. Treatment assignment was based on the randomized treatment. Assignment to the stratification factor injection site was based on the planned and not the actual used injection site.</population>
        <group_list>
          <group group_id="O1">
            <title>Dasiglucagon 0.6 mg</title>
            <description>Single fixed dose (subcutaneous injection) of dasiglucagon&#xD;
dasiglucagon: glucagon analog</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Single fixed dose (subcutaneous injection) of placebo&#xD;
placebo: placebo for dasiglucagon</description>
          </group>
          <group group_id="O3">
            <title>GlucaGen® 1.0 mg</title>
            <description>Single fixed dose (subcutaneous injection) of GlucaGen® (0.5 mg if body weight &lt;25 kg)&#xD;
GlucaGen HypoKit: native glucagon</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Glucose Recovery</title>
          <description>Plasma glucose recovery within 30 minutes, within 20 minutes, within 15 minutes, and within 10 minutes after study drug injection without administration of rescue intravenous (IV) glucose. Plasma glucose recovery was defined as the first increase in plasma glucose of ≥20 mg/dL (1.1 mmol/L) from baseline without administration of rescue intravenous glucose.</description>
          <population>Full analysis set (same as the safety analysis set) of all randomized and treated patients. Treatment assignment was based on the randomized treatment. Assignment to the stratification factor injection site was based on the planned and not the actual used injection site.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Glucose recovery at 30 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose recovery at 20 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose recovery at 15 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose recovery at 10 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The recovery rates of dasiglucagon and placebo were compared at each time point using a Cochran-Mantel-Haenszel test stratified by age group and injection site. Testing followed an a priori defined hierarchical inferential test order, proceeding until the first failure to reject the null hypothesis comparing dasiglucagon versus placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0073</p_value>
            <p_value_desc>Assessed at 30 minutes. Note that p-value was 0.0005 at 10 minutes and &lt;0.0001 at 15 and 20 minutes.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Glucose Changes From Baseline</title>
        <description>Plasma glucose changes from baseline within 30 minutes, within 20 minutes, within 15 minutes, and within 10 minutes after trial product injection or at the time of rescue intravenous (IV) glucose</description>
        <time_frame>0-30 minutes after dosing: assessed at 10, 15, 20 and 30 minutes after study drug injection</time_frame>
        <population>Full analysis set (same as the safety analysis set) of all randomized and treated patients. Treatment assignment was based on the randomized treatment. Assignment to the stratification factor injection site was based on the planned and not the actual used injection site.</population>
        <group_list>
          <group group_id="O1">
            <title>Dasiglucagon 0.6 mg</title>
            <description>Single fixed dose (subcutaneous injection) of dasiglucagon&#xD;
dasiglucagon: glucagon analog</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Single fixed dose (subcutaneous injection) of placebo&#xD;
placebo: placebo for dasiglucagon</description>
          </group>
          <group group_id="O3">
            <title>GlucaGen® 1.0 mg</title>
            <description>Single fixed dose (subcutaneous injection) of GlucaGen® (0.5 mg if body weight &lt;25 kg)&#xD;
GlucaGen HypoKit: native glucagon</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Glucose Changes From Baseline</title>
          <description>Plasma glucose changes from baseline within 30 minutes, within 20 minutes, within 15 minutes, and within 10 minutes after trial product injection or at the time of rescue intravenous (IV) glucose</description>
          <population>Full analysis set (same as the safety analysis set) of all randomized and treated patients. Treatment assignment was based on the randomized treatment. Assignment to the stratification factor injection site was based on the planned and not the actual used injection site.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At 30 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.459" spread="19.6527"/>
                    <measurement group_id="O2" value="17.510" spread="15.6313"/>
                    <measurement group_id="O3" value="85.225" spread="12.5052"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 20 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.369" spread="15.2461"/>
                    <measurement group_id="O2" value="7.322" spread="13.3543"/>
                    <measurement group_id="O3" value="58.000" spread="10.5297"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 15 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.342" spread="15.0860"/>
                    <measurement group_id="O2" value="0.835" spread="11.1276"/>
                    <measurement group_id="O3" value="40.631" spread="9.7317"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 10 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.225" spread="13.6768"/>
                    <measurement group_id="O2" value="-3.405" spread="8.0276"/>
                    <measurement group_id="O3" value="20.919" spread="6.7227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline in plasma glucose at 30, 20, 15, and 10 minutes after investigational product injection was calculated using nominal sampling times and analyzed using an analysis of variance model with treatment, age group and injection site for each endpoint. Testing followed an a priori defined hierarchical inferential test order, proceeding until the first failure to reject the null hypothesis comparing dasiglucagon versus placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p-value was &lt;0.0001 at all time points (10, 15, 20 and 30 minutes)</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamics - Area Under the Effect Curve (0-30 Minutes)</title>
        <description>Plasma glucose response as area under the effect curve above baseline from time 0 to 30 minutes (AUE0-30min). Plasma glucose was determined at pre-dose and at 4, 6, 8, 10, 12, 15, 17, 20, 30, and 45 minutes (and at 60 minutes if the patient weighed ≥21 kg) after dosing.</description>
        <time_frame>0-30 minutes</time_frame>
        <population>Full analysis set (same as the safety analysis set) of all randomized and treated patients. Treatment assignment was based on the randomized treatment. Assignment to the stratification factor injection site was based on the planned and not the actual used injection site.</population>
        <group_list>
          <group group_id="O1">
            <title>Dasiglucagon 0.6 mg</title>
            <description>Single fixed dose (subcutaneous injection) of dasiglucagon&#xD;
dasiglucagon: glucagon analog</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Single fixed dose (subcutaneous injection) of placebo&#xD;
placebo: placebo for dasiglucagon</description>
          </group>
          <group group_id="O3">
            <title>GlucaGen® 1.0 mg</title>
            <description>Single fixed dose (subcutaneous injection) of GlucaGen® (0.5 mg if body weight &lt;25 kg)&#xD;
GlucaGen HypoKit: native glucagon</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamics - Area Under the Effect Curve (0-30 Minutes)</title>
          <description>Plasma glucose response as area under the effect curve above baseline from time 0 to 30 minutes (AUE0-30min). Plasma glucose was determined at pre-dose and at 4, 6, 8, 10, 12, 15, 17, 20, 30, and 45 minutes (and at 60 minutes if the patient weighed ≥21 kg) after dosing.</description>
          <population>Full analysis set (same as the safety analysis set) of all randomized and treated patients. Treatment assignment was based on the randomized treatment. Assignment to the stratification factor injection site was based on the planned and not the actual used injection site.</population>
          <units>mmol*h/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.83" spread="6.126"/>
                    <measurement group_id="O2" value="1.81" spread="4.641"/>
                    <measurement group_id="O3" value="19.66" spread="3.410"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Administration of Rescue IV Glucose Infusion After IMP Injection</title>
        <description>Number of patients receiving IV rescue glucose administration for hypoglycemia after administration of IMP. IV = intravenous. IMP = investigational medicinal product.</description>
        <time_frame>0-45 minutes</time_frame>
        <population>Safety analysis set (same as the full analysis set) of all randomized and treated patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Dasiglucagon 0.6 mg</title>
            <description>Single fixed dose (subcutaneous injection) of dasiglucagon&#xD;
dasiglucagon: glucagon analog</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Single fixed dose (subcutaneous injection) of placebo&#xD;
placebo: placebo for dasiglucagon</description>
          </group>
          <group group_id="O3">
            <title>GlucaGen® 1.0 mg</title>
            <description>Single fixed dose (subcutaneous injection) of GlucaGen® (0.5 mg if body weight &lt;25 kg)&#xD;
GlucaGen HypoKit: native glucagon</description>
          </group>
        </group_list>
        <measure>
          <title>Administration of Rescue IV Glucose Infusion After IMP Injection</title>
          <description>Number of patients receiving IV rescue glucose administration for hypoglycemia after administration of IMP. IV = intravenous. IMP = investigational medicinal product.</description>
          <population>Safety analysis set (same as the full analysis set) of all randomized and treated patients.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First IV Glucose Infusion After IMP Administration</title>
        <description>Time to first IV rescue glucose administration for hypoglycemia after administration of IMP. IV = intravenous. IMP = investigational medicinal product.</description>
        <time_frame>0-45 minutes</time_frame>
        <population>Only the patient who received IV glucose administration is included.</population>
        <group_list>
          <group group_id="O1">
            <title>Dasiglucagon 0.6 mg</title>
            <description>Single fixed dose (subcutaneous injection) of dasiglucagon&#xD;
dasiglucagon: glucagon analog</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Single fixed dose (subcutaneous injection) of placebo&#xD;
placebo: placebo for dasiglucagon</description>
          </group>
          <group group_id="O3">
            <title>GlucaGen® 1.0 mg</title>
            <description>Single fixed dose (subcutaneous injection) of GlucaGen® (0.5 mg if body weight &lt;25 kg)&#xD;
GlucaGen HypoKit: native glucagon</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First IV Glucose Infusion After IMP Administration</title>
          <description>Time to first IV rescue glucose administration for hypoglycemia after administration of IMP. IV = intravenous. IMP = investigational medicinal product.</description>
          <population>Only the patient who received IV glucose administration is included.</population>
          <units>minutes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: AUC0-30 Min</title>
        <description>Area under the plasma dasiglucagon or GlucaGen concentration versus time curve from 0 to 30 minutes post-dose. Samples were collected before dosing and at 10, 20, 30, 40, 60, 90, 140, 220, and 300 minutes after dosing.</description>
        <time_frame>0-30 minutes</time_frame>
        <population>Full analysis set (same as the safety analysis set) of all randomized and treated patients. Treatment assignment was based on the randomized treatment. Assignment to the stratification factor injection site was based on the planned and not the actual used injection site.</population>
        <group_list>
          <group group_id="O1">
            <title>Dasiglucagon 0.6 mg</title>
            <description>Single fixed dose (subcutaneous injection) of dasiglucagon&#xD;
dasiglucagon: glucagon analog</description>
          </group>
          <group group_id="O2">
            <title>GlucaGen® 1.0 mg</title>
            <description>Single fixed dose (subcutaneous injection) of GlucaGen® (0.5 mg if body weight &lt;25 kg)&#xD;
GlucaGen HypoKit: native glucagon</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: AUC0-30 Min</title>
          <description>Area under the plasma dasiglucagon or GlucaGen concentration versus time curve from 0 to 30 minutes post-dose. Samples were collected before dosing and at 10, 20, 30, 40, 60, 90, 140, 220, and 300 minutes after dosing.</description>
          <population>Full analysis set (same as the safety analysis set) of all randomized and treated patients. Treatment assignment was based on the randomized treatment. Assignment to the stratification factor injection site was based on the planned and not the actual used injection site.</population>
          <units>h*pmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="376" spread="78.1"/>
                    <measurement group_id="O2" value="376" spread="63.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: AUC0-300min</title>
        <description>Area under the plasma dasiglucagon or GlucaGen concentration versus time curve from 0 to 300 minutes post-dose. Samples were collected before dosing and at 10, 20, 30, 40, 60, 90, 140, 220, and 300 minutes after dosing.</description>
        <time_frame>0-300 minutes</time_frame>
        <population>Full analysis set (same as the safety analysis set) of all randomized and treated patients. Treatment assignment was based on the randomized treatment. Assignment to the stratification factor injection site was based on the planned and not the actual used injection site.</population>
        <group_list>
          <group group_id="O1">
            <title>Dasiglucagon 0.6 mg</title>
            <description>Single fixed dose (subcutaneous injection) of dasiglucagon&#xD;
dasiglucagon: glucagon analog</description>
          </group>
          <group group_id="O2">
            <title>GlucaGen® 1.0 mg</title>
            <description>Single fixed dose (subcutaneous injection) of GlucaGen® (0.5 mg if body weight &lt;25 kg)&#xD;
GlucaGen HypoKit: native glucagon</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: AUC0-300min</title>
          <description>Area under the plasma dasiglucagon or GlucaGen concentration versus time curve from 0 to 300 minutes post-dose. Samples were collected before dosing and at 10, 20, 30, 40, 60, 90, 140, 220, and 300 minutes after dosing.</description>
          <population>Full analysis set (same as the safety analysis set) of all randomized and treated patients. Treatment assignment was based on the randomized treatment. Assignment to the stratification factor injection site was based on the planned and not the actual used injection site.</population>
          <units>h*pmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1810" spread="44.8"/>
                    <measurement group_id="O2" value="1370" spread="72.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: AUC0-inf</title>
        <description>Area under the plasma dasiglucagon or GlucaGen concentration versus time curve from 0 to infinitely post-dose. Samples were collected before dosing and at 10, 20, 30, 40, 60, 90, 140, 220, and 300 minutes after dosing.</description>
        <time_frame>0-300 minutes</time_frame>
        <population>Full analysis set (same as the safety analysis set) of all randomized and treated patients. Treatment assignment was based on the randomized treatment. Assignment to the stratification factor injection site was based on the planned and not the actual used injection site.</population>
        <group_list>
          <group group_id="O1">
            <title>Dasiglucagon 0.6 mg</title>
            <description>Single fixed dose (subcutaneous injection) of dasiglucagon&#xD;
dasiglucagon: glucagon analog</description>
          </group>
          <group group_id="O2">
            <title>GlucaGen® 1.0 mg</title>
            <description>Single fixed dose (subcutaneous injection) of GlucaGen® (0.5 mg if body weight &lt;25 kg)&#xD;
GlucaGen HypoKit: native glucagon</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: AUC0-inf</title>
          <description>Area under the plasma dasiglucagon or GlucaGen concentration versus time curve from 0 to infinitely post-dose. Samples were collected before dosing and at 10, 20, 30, 40, 60, 90, 140, 220, and 300 minutes after dosing.</description>
          <population>Full analysis set (same as the safety analysis set) of all randomized and treated patients. Treatment assignment was based on the randomized treatment. Assignment to the stratification factor injection site was based on the planned and not the actual used injection site.</population>
          <units>h*pmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1850" spread="45.1"/>
                    <measurement group_id="O2" value="1530" spread="70.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Cmax</title>
        <description>Maximum of all valid plasma dasiglucagon or GlucaGen concentration measurements from 0 to 300 minutes post-dose. Samples were collected before dosing and at 10, 20, 30, 40, 60, 90, 140, 220, and 300 minutes after dosing.</description>
        <time_frame>0-300 minutes</time_frame>
        <population>Full analysis set (same as the safety analysis set) of all randomized and treated patients. Treatment assignment was based on the randomized treatment. Assignment to the stratification factor injection site was based on the planned and not the actual used injection site.</population>
        <group_list>
          <group group_id="O1">
            <title>Dasiglucagon 0.6 mg</title>
            <description>Single fixed dose (subcutaneous injection) of dasiglucagon&#xD;
dasiglucagon: glucagon analog</description>
          </group>
          <group group_id="O2">
            <title>GlucaGen® 1.0 mg</title>
            <description>Single fixed dose (subcutaneous injection) of GlucaGen® (0.5 mg if body weight &lt;25 kg)&#xD;
GlucaGen HypoKit: native glucagon</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Cmax</title>
          <description>Maximum of all valid plasma dasiglucagon or GlucaGen concentration measurements from 0 to 300 minutes post-dose. Samples were collected before dosing and at 10, 20, 30, 40, 60, 90, 140, 220, and 300 minutes after dosing.</description>
          <population>Full analysis set (same as the safety analysis set) of all randomized and treated patients. Treatment assignment was based on the randomized treatment. Assignment to the stratification factor injection site was based on the planned and not the actual used injection site.</population>
          <units>pmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1160" spread="61.2"/>
                    <measurement group_id="O2" value="1120" spread="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Tmax</title>
        <description>Time to maximum of plasma dasiglucagon or GlucaGen concentration measurements. Samples were collected before dosing and at 10, 20, 30, 40, 60, 90, 140, 220, and 300 minutes after dosing.</description>
        <time_frame>0-300 minutes</time_frame>
        <population>Full analysis set (same as the safety analysis set) of all randomized and treated patients. Treatment assignment was based on the randomized treatment. Assignment to the stratification factor injection site was based on the planned and not the actual used injection site.</population>
        <group_list>
          <group group_id="O1">
            <title>Dasiglucagon 0.6 mg</title>
            <description>Single fixed dose (subcutaneous injection) of dasiglucagon&#xD;
dasiglucagon: glucagon analog</description>
          </group>
          <group group_id="O2">
            <title>GlucaGen® 1.0 mg</title>
            <description>Single fixed dose (subcutaneous injection) of GlucaGen® (0.5 mg if body weight &lt;25 kg)&#xD;
GlucaGen HypoKit: native glucagon</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Tmax</title>
          <description>Time to maximum of plasma dasiglucagon or GlucaGen concentration measurements. Samples were collected before dosing and at 10, 20, 30, 40, 60, 90, 140, 220, and 300 minutes after dosing.</description>
          <population>Full analysis set (same as the safety analysis set) of all randomized and treated patients. Treatment assignment was based on the randomized treatment. Assignment to the stratification factor injection site was based on the planned and not the actual used injection site.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35" lower_limit="0.167" upper_limit="1.5"/>
                    <measurement group_id="O2" value="0.333" lower_limit="0.167" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: λz</title>
        <description>Terminal elimination rate constant of plasma dasiglucagon or GlucaGen. Samples were collected before dosing and at 10, 20, 30, 40, 60, 90, 140, 220, and 300 minutes after dosing.</description>
        <time_frame>0-300 minutes</time_frame>
        <population>Full analysis set (same as the safety analysis set) of all randomized and treated patients. Treatment assignment was based on the randomized treatment. Assignment to the stratification factor injection site was based on the planned and not the actual used injection site.</population>
        <group_list>
          <group group_id="O1">
            <title>Dasiglucagon 0.6 mg</title>
            <description>Single fixed dose (subcutaneous injection) of dasiglucagon&#xD;
dasiglucagon: glucagon analog</description>
          </group>
          <group group_id="O2">
            <title>GlucaGen® 1.0 mg</title>
            <description>Single fixed dose (subcutaneous injection) of GlucaGen® (0.5 mg if body weight &lt;25 kg)&#xD;
GlucaGen HypoKit: native glucagon</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: λz</title>
          <description>Terminal elimination rate constant of plasma dasiglucagon or GlucaGen. Samples were collected before dosing and at 10, 20, 30, 40, 60, 90, 140, 220, and 300 minutes after dosing.</description>
          <population>Full analysis set (same as the safety analysis set) of all randomized and treated patients. Treatment assignment was based on the randomized treatment. Assignment to the stratification factor injection site was based on the planned and not the actual used injection site.</population>
          <units>1/hour</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.11" spread="37.4"/>
                    <measurement group_id="O2" value="0.504" spread="27.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: t½</title>
        <description>Terminal plasma elimination half-life of dasiglucagon or GlucaGen. Samples were collected before dosing and at 10, 20, 30, 40, 60, 90, 140, 220, and 300 minutes after dosing.</description>
        <time_frame>0-300 minutes</time_frame>
        <population>Full analysis set (same as the safety analysis set) of all randomized and treated patients. Treatment assignment was based on the randomized treatment. Assignment to the stratification factor injection site was based on the planned and not the actual used injection site.</population>
        <group_list>
          <group group_id="O1">
            <title>Dasiglucagon 0.6 mg</title>
            <description>Single fixed dose (subcutaneous injection) of dasiglucagon&#xD;
dasiglucagon: glucagon analog</description>
          </group>
          <group group_id="O2">
            <title>GlucaGen® 1.0 mg</title>
            <description>Single fixed dose (subcutaneous injection) of GlucaGen® (0.5 mg if body weight &lt;25 kg)&#xD;
GlucaGen HypoKit: native glucagon</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: t½</title>
          <description>Terminal plasma elimination half-life of dasiglucagon or GlucaGen. Samples were collected before dosing and at 10, 20, 30, 40, 60, 90, 140, 220, and 300 minutes after dosing.</description>
          <population>Full analysis set (same as the safety analysis set) of all randomized and treated patients. Treatment assignment was based on the randomized treatment. Assignment to the stratification factor injection site was based on the planned and not the actual used injection site.</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.623" spread="37.4"/>
                    <measurement group_id="O2" value="1.38" spread="27.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: CL/f</title>
        <description>Total body clearance of plasma dasiglucagon or GlucaGen. Samples were collected before dosing and at 10, 20, 30, 40, 60, 90, 140, 220, and 300 minutes after dosing.</description>
        <time_frame>0-300 minutes</time_frame>
        <population>Full analysis set (same as the safety analysis set) of all randomized and treated patients. Treatment assignment was based on the randomized treatment. Assignment to the stratification factor injection site was based on the planned and not the actual used injection site.</population>
        <group_list>
          <group group_id="O1">
            <title>Dasiglucagon 0.6 mg</title>
            <description>Single fixed dose (subcutaneous injection) of dasiglucagon&#xD;
dasiglucagon: glucagon analog</description>
          </group>
          <group group_id="O2">
            <title>GlucaGen® 1.0 mg</title>
            <description>Single fixed dose (subcutaneous injection) of GlucaGen® (0.5 mg if body weight &lt;25 kg)&#xD;
GlucaGen HypoKit: native glucagon</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: CL/f</title>
          <description>Total body clearance of plasma dasiglucagon or GlucaGen. Samples were collected before dosing and at 10, 20, 30, 40, 60, 90, 140, 220, and 300 minutes after dosing.</description>
          <population>Full analysis set (same as the safety analysis set) of all randomized and treated patients. Treatment assignment was based on the randomized treatment. Assignment to the stratification factor injection site was based on the planned and not the actual used injection site.</population>
          <units>L/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.1" spread="45.1"/>
                    <measurement group_id="O2" value="188" spread="70.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Vz/f</title>
        <description>Volume of distribution of plasma dasiglucagon or GlucaGen. Samples were collected before dosing and at 10, 20, 30, 40, 60, 90, 140, 220, and 300 minutes after dosing.</description>
        <time_frame>0-300 minutes</time_frame>
        <population>Full analysis set (same as the safety analysis set) of all randomized and treated patients. Treatment assignment was based on the randomized treatment. Assignment to the stratification factor injection site was based on the planned and not the actual used injection site.</population>
        <group_list>
          <group group_id="O1">
            <title>Dasiglucagon 0.6 mg</title>
            <description>Single fixed dose (subcutaneous injection) of dasiglucagon&#xD;
dasiglucagon: glucagon analog</description>
          </group>
          <group group_id="O2">
            <title>GlucaGen® 1.0 mg</title>
            <description>Single fixed dose (subcutaneous injection) of GlucaGen® (0.5 mg if body weight &lt;25 kg)&#xD;
GlucaGen HypoKit: native glucagon</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Vz/f</title>
          <description>Volume of distribution of plasma dasiglucagon or GlucaGen. Samples were collected before dosing and at 10, 20, 30, 40, 60, 90, 140, 220, and 300 minutes after dosing.</description>
          <population>Full analysis set (same as the safety analysis set) of all randomized and treated patients. Treatment assignment was based on the randomized treatment. Assignment to the stratification factor injection site was based on the planned and not the actual used injection site.</population>
          <units>litres</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.4" spread="62.2"/>
                    <measurement group_id="O2" value="373" spread="81.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: MRT</title>
        <description>Mean residence time of plasma dasiglucagon or GlucaGen. Samples were collected before dosing and at 10, 20, 30, 40, 60, 90, 140, 220, and 300 minutes after dosing.</description>
        <time_frame>0-300 minutes</time_frame>
        <population>Full analysis set (same as the safety analysis set) of all randomized and treated patients. Treatment assignment was based on the randomized treatment. Assignment to the stratification factor injection site was based on the planned and not the actual used injection site.</population>
        <group_list>
          <group group_id="O1">
            <title>Dasiglucagon 0.6 mg</title>
            <description>Single fixed dose (subcutaneous injection) of dasiglucagon&#xD;
dasiglucagon: glucagon analog</description>
          </group>
          <group group_id="O2">
            <title>GlucaGen® 1.0 mg</title>
            <description>Single fixed dose (subcutaneous injection) of GlucaGen® (0.5 mg if body weight &lt;25 kg)&#xD;
GlucaGen HypoKit: native glucagon</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: MRT</title>
          <description>Mean residence time of plasma dasiglucagon or GlucaGen. Samples were collected before dosing and at 10, 20, 30, 40, 60, 90, 140, 220, and 300 minutes after dosing.</description>
          <population>Full analysis set (same as the safety analysis set) of all randomized and treated patients. Treatment assignment was based on the randomized treatment. Assignment to the stratification factor injection site was based on the planned and not the actual used injection site.</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.27" spread="29.5"/>
                    <measurement group_id="O2" value="1.86" spread="21.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from the first trial-related activity after the patient had signed the informed consent to the end of the follow-up period (28 days).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Age Group 6-11 Years - Dasiglucagon</title>
          <description>Patients in the dasiglucagon group in the age group 6-11 years</description>
        </group>
        <group group_id="E2">
          <title>Age Group 6-11 Years - Placebo</title>
          <description>Patients in the placebo group in the age group 6-11 years</description>
        </group>
        <group group_id="E3">
          <title>Age Group 6-11 Years - GlucaGen</title>
          <description>Patients in the GlucaGen group in the age group 6-11 years</description>
        </group>
        <group group_id="E4">
          <title>Age Group 12-17 Years - Dasiglucagon</title>
          <description>Patients in the dasiglucagon group in the age group 12-17 years</description>
        </group>
        <group group_id="E5">
          <title>Age Group 12-17 Years - Placebo</title>
          <description>Patients in the placebo group in the age group 12-17 years</description>
        </group>
        <group group_id="E6">
          <title>Age Group 12-17 Years - Glucagen</title>
          <description>Patients in the GlucaGen group in the age group 12-17 years</description>
        </group>
        <group group_id="E7">
          <title>Dasiglucagon 0.6 mg</title>
          <description>Full population. Single fixed dose (subcutaneous injection) of dasiglucagon</description>
        </group>
        <group group_id="E8">
          <title>Placebo</title>
          <description>Full population. Single fixed dose (subcutaneous injection) of placebo</description>
        </group>
        <group group_id="E9">
          <title>GlucaGen® 1.0 mg</title>
          <description>Full population. Single fixed dose (subcutaneous injection) of GlucaGen® (0.5 mg if body weight &lt;25 kg)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="15" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E4" events="12" subjects_affected="11" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="14" subjects_affected="13" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="11" subjects_affected="8" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="13" subjects_affected="10" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Injection site edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Infusion site bruising</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Infusion site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="3" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="16" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E8" events="16" subjects_affected="4" subjects_at_risk="11"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Kim Mark Knudsen</name_or_title>
      <organization>Zealand Pharma A/S</organization>
      <phone>+4550603780</phone>
      <email>KMKnudsen@zealandpharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

